Roundtable Discussion: Investigating the Essential Features of Clinical Trials to Streamline mRNA Cancer Vaccines Through the Clinic & Into the Patient

Time: 3:15 pm
day: Conference Day One


  • Considering the selection of appropriate patient populations for the clinical trial who will have a high likelihood of benefiting from the vaccine, while also ensuring that the patient population is diverse enough to accurately represent the general population
  • Determining the appropriate dosage and schedule for administering the vaccine, as well as defining the primary and secondary endpoints for the trial
  • Monitoring potential adverse effects and ensuring that the vaccine is able to elicit a robust immune response against the targeted cancer cells